Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11478208 | 0.85 | CA2 (0.44) | MEN1KMT2AALDH1A1HSD17B10TDP1 | |
| SCHEMBL20326463 | 0.84 | AKR1C3 (0.45) | MEN1KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL25678903 | 0.83 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL1031243 | 0.82 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1HSD17B10PKM | |
| SCHEMBL1031298 | 0.82 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1HSD17B10PKM | |
| SCHEMBL24600167 | 0.82 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1HSD17B10TDP1 | |
| SCHEMBL1027356 | 0.82 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1HSD17B10PKM | |
| SCHEMBL6894333 | 0.82 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL10180572 | 0.82 | MEN1 (0.46) | MEN1KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL14226496 | 0.82 | NR1I2 (0.47) | ALDH1A1HSD17B10GAATDP1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659017-B | TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2026-05-15 | — | — | CN | disclosed |
| CN-115843271-B | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2024-08-13 | — | — | CN | disclosed |
| CN-117659017-A | TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2024-03-08 | — | — | CN | disclosed |
| CN-115843271-A | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2023-03-24 | — | — | CN | disclosed |
| US-9672952-B2 | Polymer and conductive composition | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-06-06 | — | — | US | disclosed |
| US-9672952-B2 | Polymer and conductive composition | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-06-06 | — | — | US | disclosed |
| US-20150048278-A1 | POLYMER AND CONDUCTIVE COMPOSITION | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2015-02-19 | — | — | US | disclosed |
| US-20150048278-A1 | POLYMER AND CONDUCTIVE COMPOSITION | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2015-02-19 | — | — | US | disclosed |
| CN-101039904-B | Is suitable for treating dopamine D3Heterocyclic compounds for receptor-modulated responsive disorders | ABBOTT GMBH & CO KG | 2014-09-24 | — | — | CN | disclosed |
| US-20140179875-A1 | SULFURIZATION REAGENTS ON SOLID SUPPORTS | GIRINDUS AMERICA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2009017719-A2 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-02-21 | — | — | US | disclosed |
| CN-101039904-A | Is suitable for treating dopamine D3Heterocyclic compounds for receptor-modulated responsive disorders | ABBOTT GMBH & CO KG (DE) | 2007-09-19 | — | — | CN | disclosed |
| EP-1814849-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006040182-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| EP-1051655-B1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | ISTA PHARMACEUTICALS INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20010016731-A1 | Methods and apparatus for accelerated orthokeratology | DEVORE DALE (US) | 2001-08-23 | — | — | US | disclosed |
| CN-1295677-A | Method and apparatus for accelerated orthokeratology | EASTA PHARMACEUTICALS INC (US) | 2001-05-16 | — | — | CN | disclosed |
| US-6161544-A | Methods for accelerated orthokeratology | KERATOFORM, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| US-4006186-A | MULTISTAGE FROM A PHENYLSULFONYL CHLORIDE AND HYDRAZINE | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | DRD3, MC3R, CHRNA3 | MEN1 2369/4885KMT2A 2936/4885ALDH1A1 1263/4885 |
| US-20140179875-A1 | SULFURIZATION REAGENTS ON SOLID SUPPORTS | OR10J3, RPS8, NSUN2 | MEN1 3365/4885KMT2A 1067/4885ALDH1A1 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.